EZH2 inhibition for epithelioid sarcoma and follicular lymphoma

Lancet Oncol. 2020 Nov;21(11):1388-1390. doi: 10.1016/S1470-2045(20)30530-1. Epub 2020 Oct 6.

Authors

Roman Groisberg¹, Vivek Subbiah²

Affiliations

¹ Department of Melanoma and Sarcoma Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
² Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, the University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: vsubbiah@mdanderson.org.

PMID: 33035458
DOI: 10.1016/S1470-2045(20)30530-1

No abstract available

Publication types

Comment

MeSH terms

Benzamides
Biphenyl Compounds
Enhancer of Zeste Homolog 2 Protein / genetics
Humans
Lymphoma, Follicular* / drug therapy
Morpholines
Pyridones
Sarcoma* / drug therapy
Sarcoma* / genetics

Substances

Benzamides
Biphenyl Compounds
Morpholines
Pyridones
EZH2 protein, human
Enhancer of Zeste Homolog 2 Protein
tazemetostat